Table 1.
Polymorphic CYP substrates within the ISS drug list: Information about involvement of polymorphic drug metabolism from the drug labels or from evidence-based pharmacogenetic guidelines.
Among the drugs listed in the ISS repository, specific warnings related to pharmacokinetic effects have been identified in the label section of 14 drugs. For six drugs on the list, specific therapy modifications (alternative drugs) or dosing adjustments are proposed in existing evidence-based guidelines.
Fig 1.
The main enzymes or transporters involved in elimination of the drugs listed in the ISS drug repository.
The number of drugs metabolized mainly by the respected enzyme or transporter corresponds to the size of the circle partitions. The retracted slices of the circle are enzymes with known genetic polymorphisms and empirical data for the formulation of therapeutic recommendations or dose adjustments.